Ann: Half Year Accounts, page-137

Finally!......someone who "unlike the others" can give me a genuine explanation for their rationalisation however again yet to explain it.
So thanks, but you only answer part of the question in that you are not basing it on anything that stands out in the 4C but basing this stock against a profitable, scaleable business model.
So are you able to expand or elaborate further on what that looks like for this sector & what was it in CNW & MWR that made you realise their path to profit was attainable using this method?

Will the MM side provide the path? I don't know, thus the questions. So far the Medcan deal has gone back to a deal where CGB is putting money in and gets no ownership, which seems like a poor deal. Beyond Medcan, I can't see where CGB has licenses to manufacturer, export and eventually Sell, and even Medcan I believe is missing 1 permit?

I think you will find there is a lot more to your statement here & that indeed there will be MM on the agenda in the near future for CGB. They were quick to pivot to a facility in Biohealth (Pharmocann/Canntab deals) to help accelerate a path to profit IMO keeping Medcan on the side currently working with the seedbank etc. I think you will also find the Pharmocann deal came to the table through MCL & the Feldmans & that the original deal with Bonify will indeed remain on the table. Of course much of this is my opinion which comes from research, discussion with staff & then gut feel. We all have our methods for investing & I love good stories such as yours with CNW & MWR. My best ever was a little company called MDL which went from a purchase of 2 cents to I think $2.67 when I sold many years ago. PS: Lot's of good luck involved too I reckon